| __timestamp | Arrowhead Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 242549000 |
| Thursday, January 1, 2015 | 57410147 | 245098000 |
| Friday, January 1, 2016 | 41454452 | 147600000 |
| Sunday, January 1, 2017 | 31690298 | 264600000 |
| Monday, January 1, 2018 | 52968505 | 357900000 |
| Tuesday, January 1, 2019 | 81048686 | 1182600000 |
| Wednesday, January 1, 2020 | 128874979 | 357700000 |
| Friday, January 1, 2021 | 206342000 | 540100000 |
| Saturday, January 1, 2022 | 297307000 | 322900000 |
| Sunday, January 1, 2023 | 353188000 | 408000000 |
| Monday, January 1, 2024 | 505870000 |
In pursuit of knowledge
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, United Therapeutics Corporation and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting yet compelling R&D investment strategies. From 2014 to 2023, United Therapeutics consistently allocated substantial resources, peaking in 2019 with a remarkable 1.18 billion dollars, underscoring their commitment to groundbreaking therapies. Meanwhile, Arrowhead Pharmaceuticals exhibited a dynamic growth trajectory, with R&D expenses surging by over 2,000% from 2014 to 2024, reflecting their aggressive pursuit of novel RNAi-based treatments. Notably, 2024 data for United Therapeutics is unavailable, leaving room for speculation on their future direction. This comparative analysis highlights the strategic priorities of these industry leaders, offering insights into their potential impact on healthcare advancements.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
United Therapeutics Corporation vs Exelixis, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Arrowhead Pharmaceuticals, Inc. and Novavax, Inc.